Primary CXCR4 Co-receptor Use in Acute HIV Infection Leads to Rapid Disease Progression in the AE Subtype

被引:15
|
作者
Jiao, Yanmei [1 ]
Song, Yingxue [1 ]
Kou, Buxin [1 ]
Wang, Rui [1 ]
Liu, Zhiying [1 ]
Huang, Xiaojie [1 ]
Chen, Dexi [1 ]
Zhang, Tong [1 ]
Wu, Hao [1 ]
机构
[1] Capital Med Univ, Beijing You An Hosp, Ctr Infect Dis, Beijing 100069, Peoples R China
基金
中国国家自然科学基金;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; V3 LOOP SEQUENCES; GENOTYPIC PREDICTION; CHEMOKINE RECEPTORS; ENV PROTEIN; GP120; ENV; PHENOTYPE; TROPISM; USAGE; TOOLS;
D O I
10.1089/vim.2012.0035
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This is a comparative study of HIV co-receptor usage in the early stages of HIV infection between two distinct patient groups, one with a low CD4 count (group 1), and the other with a high CD4 count (group 2). Group 1 progressed to a CD4 count below 200 cells/mu L within 2 y, while group 2 had a CD4 count above 500 cells/mu L within 2 y. Viral RNA was extracted from the plasma of these patients, and the C2-V5 region of the HIV-1 env genes were cloned and sequenced. The co-receptor usage was predicated based on V3 loop amino acid sequences using Geno2pheno and PSSM programs. Our results indicate that in acute HIV infection of rapid progressors (low CD4 count; group 1), the primary co-receptor usage is CXCR4, while in the high CD4 count group (group 2), the co-receptor usage is predominantly CCR5. One-year follow-up data from these patients showed no obvious change in HIV co-receptor usage in either group. Sequence analysis of patients from both study groups showed prevalence of the AE subtype, and therefore we can speculate that the CXCR4 co-receptor may be the primary HIV-1 co-receptor used in the HIV-1 AE subtype, and may be responsible for rapid HIV-1 disease progression in the MSM cohort.
引用
收藏
页码:262 / 267
页数:6
相关论文
共 50 条
  • [31] WHIM Syndrome, a combined immunodeficiency disease, is caused by mutations in the HIV co-receptor gene CXCR4.
    Hernandez, PA
    Gorlin, RG
    Lukens, JN
    Diaz, GA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 217 - 217
  • [32] CD4: A co-receptor in the immune response and HIV infection
    Bowers, K
    Pitcher, C
    Marsh, M
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1997, 29 (06): : 871 - 875
  • [33] Enhanced expression of the CXCR4 co-receptor in HIV-1-infected individuals correlates with the emergence of syncytia-inducing strains
    Manetti, R
    Cosmi, L
    Galli, G
    Annunziato, F
    Mazzetti, M
    Romagnani, S
    Maggi, E
    CYTOKINES CELLULAR & MOLECULAR THERAPY, 2000, 6 (01) : 19 - 24
  • [34] CXCR4 Blockade Targets Progression of Primary T Cell Acute Lymphoblastic Leukemia
    Tikhonova, Anastasia N.
    BLOOD, 2022, 140 : 11666 - 11667
  • [35] Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy
    Chen, JD
    Bai, XF
    Yang, AG
    Cong, YP
    Chen, SY
    NATURE MEDICINE, 1997, 3 (10) : 1110 - 1116
  • [36] Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy
    Ji-Dai Chen
    Xuefan Bai
    An-Gang Yang
    Yanping Cong
    Si-Yi Chen
    Nature Medicine, 1997, 3 : 1110 - 1116
  • [37] Lead Screening for CXCR4 of the Human HIV Infection Receptor Inhibited by Traditional Chinese Medicine
    Hung, Tzu-Chieh
    Lee, Wen-Yuan
    Chen, Kuen-Bao
    Chen, Calvin Yu-Chian
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [38] CXCR4 receptor antagonist, AMD3100, is a potent inhibitor of HIV infection.
    De Clercq, E
    Schols, D
    Bridger, G
    Henson, G
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U5 - U5
  • [39] Position 22 of the V3 Loop is Associated with Co-Receptor Usage and Disease Progression in HIV-1 Subtype B Isolates
    Zhou, Hai-Zhou
    Xu, Hua-Feng
    Xin, Xiao-Min
    Guan, Xiu-Ru
    Zhou, Jin
    CURRENT HIV RESEARCH, 2011, 9 (08) : 636 - 641
  • [40] Virus resistance to the CXCR4 inhibitor AMD070 develops slowly and does not induce a co-receptor switch
    Vermeire, K
    Hatse, S
    Princen, K
    De Clercq, E
    Calandra, G
    Skerlj, R
    Bridger, G
    Schols, D
    ANTIVIRAL RESEARCH, 2004, 62 (02) : A42 - A43